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Abstract 
The mitochondrial phosphate carrier (PiC) is a mitochondrial solute carrier protein, 
which is encoded by SLC25A3 in humans. PiC delivers phosphate, a key substrate of 
oxidative phosphorylation, across the inner mitochondrial membrane. This transport 
activity is also relevant for allowing effective mitochondrial calcium handling. 
Furthermore, PiC has also been described to affect cell survival mechanisms via 
interactions with cyclophilin D and the viral mitochondrial-localized inhibitor of apoptosis 
(vMIA). The significance of PiC has been supported by the recent discovery of a fatal 
human condition associated with PiC mutations. Here, we present first the early studies 
that lead to the discovery and molecular characterization of the PiC, then discuss the 
very recently developed mouse models for PiC and pathological mutations in the human 




From measurements of mitochondrial swelling in sucrose or mannitol media, it was 
recognized very early on that the mitochondrial volume was not freely accessible to 
even small solutes [1, 2]. By varying the concentration of sucrose, it was further 
determined that the outer mitochondrial membrane (OMM) was quite permeant (<5 kDa) 
and that it was the inner mitochondrial membrane (IMM) that provided the barrier to 
solute movement [3]. Subsequently, and in parallel with studies to sort out oxidative 
phosphorylation, great efforts were made to understand the transport of solutes across 
the IMM. Earlier studies had already demonstrated that exogenous inorganic phosphate 
(Pi) was required to drive oxidative phosphorylation [4, 5]. Clearly, Pi was of importance 
as an anion whose transport mechanism across the IMM was in need of definition.  
 
Functional characterization of Pi transport in mitochondria 
It was again through the use of simple swelling experiments, as well as by measuring 
mitochondrial respiration in the presence of thiol-reactive mercurial compounds, that Pi 
transport across the IMM was initially characterized. For swelling experiments, 
mitochondria were suspended in iso-osmotic solutions containing an anion and a cation 
(plus EGTA and rotenone); swelling occurred only when both the anion and the cation 
permeated the mitochondria. Using this method, Chappell and co-workers determined, 
using NH4 as the cation, that mitochondria were permeable to Pi and postulated the 
existence of a carrier system for Pi uptake [2, 6]. At the same time, Fonyo and Bessman 
[7] sought to understand the basis for the inhibitory action of mercurial compounds on 
“the energy transfer sequence”; such an inhibition had been described earlier by 
Lehninger and Boyer [8-10]. This first study by Fonyo and Bessman, along with follow-
up studies by Fonyo and colleagues and by Tyler, suggested that mercurial compounds 
suppressed respiration by inhibiting Pi uptake across the IMM [7, 11, 12]. Tyler further 
demonstrated that exogenous cysteine reverses the inhibitory effect of the mercurial 
compound, mersalyl, on respiration, and concluded that it was acting on a protein and 
that the inhibitory effect on respiration was not due to irreversible protein denaturation 
[12]. Then, using swelling experiments, with inactive respiration and ATP/ADP 
exchange, mersalyl was shown to prevent the swelling of mitochondria suspended in a 
solution of ammonium phosphate but not of other permeant ammonium salts [13]. It was 
subsequently established that H2PO4- is the transported species [14], and that it is 
exchanged for OH-, or taken up in symport with H+; either way, the uptake of Pi is 
electroneutral (Figure 1). The above studies measured Pi transport indirectly. The first 
direct measurements of Pi transport kinetics were undertaken by Coty and Pedersen 
using an “inhibitor-stop” assay which was performed at 0°C, and revealed Pi transport to 
be extremely rapid [15]. Indeed, the turnover number was estimated to be 50,000 per 
second at 25°C, which is extremely high among carriers [16]. 
 
Purification of the phosphate transport protein 
Hofmann and Kadenbach, using rat liver mitochondria, isolated a candidate Pi 
transporter that was estimated to be ~31 kDa [17]. Their approach relied in part on the 
use of mersalyl, which at low concentration did not inhibit Pi transport but protected 
against irreversible SH reagents [18]. Further studies indicated that the 31 kDa band 
was in fact multiple bands. Therefore, Durand’s group and also Wohlrab refined the 
above technique by combining radioactive NEM, or mersalyl coupled to an agarose 
matrix, with hydroxylapatite which, during other purification attempts, was recognized as 
having a very low affinity for the Pi carrier. This was a more straightforward approach 
that apparently yielded a single protein band in one case [19] and two bands in another 
case [20]. In the latter study, the lower molecular weight band was easily confirmed as 
the adenine nucleotide translocase (ANT) [21], whereas the higher molecular weight 
band was identified, by reconstituting the protein into liposomes then measuring 32P 
transport, as the Pi carrier. Furthermore, because molecular weight markers were used, 
the molecular weight of the Pi carrier was revised from ~31 to ~34 kDa.    
 
Kadenbach’s group observed that the reconstituted Pi transport activity measured by 
Wohlrab was very low (maximal rate just below 1 umol/min/mg protein; [20]). 
Subsequently, Pi carrier activity was found to depend on cardiolipin. When purified 
protein was reconstituted into liposomes, the addition of mitochondrial phospholipids 
almost doubled the phosphate transport rate [22, 23]. The effect was specific to 
cardiolipin because other phospholipids, including acidic ones, were ineffective [22]. 
Moreover, the activity of recombinant PiC could be increased by more than 5 times by 
adding ~7% purified cardiolipin to liposomes [24], decreasing the likelihood of an 
indirect effect of contaminants in mitochondrial phospholipid preparations. Palmieri used 
this specific requirement for cardiolipin to attempt to better isolate the Pi carrier [25]; 
indeed, higher resolution SDS gels had revealed multiple bands at ~33-34 kDa, despite 
the use of hydroxylapatite [26-28]. Inclusion of cardiolipin in the hydroxylapatite elution 
buffer largely resolved this issue, and also greatly enhanced protein recovery [25].  
 
Cloning and molecular characterization of the PiC protein 
PiC was first cloned from bovine heart [29] and subsequently, from rat liver [30] and 
human heart [31]. Further work demonstrated alternatively spliced forms in human and 
bovine tissues, giving rise to PiC-A and PiC-B isoforms, which show muscle-specific 
and broad tissue range expression, respectively [32, 33]. Based on the sequence and 
biochemical evidence, PiC has 6 transmembrane domains and its N and C termini are 
within the matrix, giving rise to a threefold symmetric organization [29]. It was 
recognized at the time of the sequencing that PiC is structurally similar to other IMM 
carrier proteins, the ANT and UCP1 (uncoupling protein 1) [29, 34]. This cohort of IMM 
proteins is known as mitochondrial carrier (MC) proteins [35, 36]. Many MCs of known 
function belong to the same protein family (encoded by slc25a3 genes), since their 
polypeptide chains consist of three tandemly related sequences of about 100 amino 
acids, and the repeats of the different carriers are homologous. They probably function 
as homodimers, each monomer being folded in the membrane into six transmembrane 
segments.  Some MCs have isoforms encoded by different slc25a genes, whereas PiC 
has two tissue-specific variants arising from a single gene by mutually exclusive 
alternative splicing of slc25a3 exon 3. Human SLC25A3 is located at chromosome 
12q23. PiC protein consists of 362 (isoform A) or 361 (isoform B) amino acids, and the 
2 splice variants encoded by exon 3A and 3B are formed by 42 and 41 amino acids, 
respectively which show 70% sequence identity. 
 
SLC25A3 has a single transcriptional initiation site and lacks a TATA box but displays 
an activation domain (-223/-25) and an inhibition domain (-1017/-814). The most 
effective promoter activity in transfected HeLa cells corresponds to the region 
containing putative binding sites for Sp1 (-163/-142; where Sp1 stands for stimulating 
protein-1) and CREB (-138/-116) [37]. 
 
Role of the PiC in oxidative phosphorylation 
Few studies aimed to establish the specific role of the PiC in oxidative phosphorylation. 
Rather, it was already understood that exogenous Pi was needed for oxidative 
phosphorylation, and respiration (both phosphorylating and uncoupled) was used as an 
outcome measure to study Pi transport across the IMM. However, Fonyo and Ligeti 
investigated the role of Pi in cation uptake using mersalyl and NEM, and concluded that 
PiC was an important H+ donor for respiration [38] (Figure 1). A small early onset burst 
remained in the presence of mersalyl, and this was found to be inhibited by 
butylmalonate, an inhibitor of the dicarboxylate carrier (DIC) which catalyzes the 
exchange of dicarboxylic acids (e.g., malate or succinate) for Pi [39]. It was concluded 
that both the PiC and the DIC have the possibility to support cation-stimulated 
respiration [40]. 
 
The functional importance of the PiC was first demonstrated in yeast (S. cerevisiae) that 
exhibited delayed growth or failed to grow on non-fermentable substrate when deleted 
for MIR1, the yeast homologue of PiC [41] or for MIR1 and PIC2 [42], respectively. PIC2 
encodes a second mitochondrial Pi carrier in yeast and also in Arabidopsis thaliana, 
shares 40% homology to mir1, and appears to play a role under certain stress 
conditions [43]. That these yeast mutants fail to thrive specifically when grown in the 
presence of mitochondrial substrates suggests the relevance of the yeast homologs of 
the PiC for oxidative phosphorylation. It is only very recently that the role of the PiC in 
ATP production and oxidative phosphorylation has been confirmed in mammals. This 
was achieved using mouse models of PiC depletion [44, 45] and by studying a loss-of-
function mutation in the human SLC25A3 gene [42] (see below). 
 
An interesting line of recent evidence has implicated PiC as a mediator of inhibition of 
oxidative phosphorylation and cytopathic effect by a viral protein. Specifically, vMIA, an 
anti-apoptotic cytomegalovirus protein was shown to lower the cellular ATP level and 
inhibit the ADP-stimulated respiratory activity. No change was observed in the 
abundance or activity of the F1F0 ATP synthase or in ANT. The abundance of the PiC 
was also unaltered but the mitochondrial Pi uptake and Pi-stimulated ATP synthesis 
were suppressed [46]. Thus, PiC might serve as a target for the effect of viral infection 
on oxidative phosphorylation.  
 
Role of PiC in calcium handling 
The highly negative inner membrane potential (m) presents a robust driving force for 
mitochondrial Ca2+ uptake. Ca2+ uptake occurs as uniport and is mediated by the 
mitochondrial calcium uniporter (mtCU) across the IMM (Figure 1). The mtCU is a highly 
Ca2+ selective ion channel formed by oligomers of pore forming MCU proteins and 
regulatory proteins (Figure 1) [47-49]. Mitochondrial Ca2+ uptake results in 
physiologically relevant [Ca2+] changes in both cytoplasm and mitochondrial matrix [50-
52]. During cytoplasmic [Ca2+] ([Ca2+]c)  elevations, strategically localized mitochondrial 
Ca2+ sequestration affects the spatial and temporal pattern of the [Ca2+]c signal, 
modulating a range of processes including muscle contraction and nerve function. 
Mitochondrial Ca2+ uptake also gives rise to a [Ca2+] increase in the mitochondrial matrix 
([Ca2+]m), which controls oxidative metabolism through the Ca2+ sensitive mitochondrial 
matrix dehydrogenase enzymes and the pyruvate dehydrogenase phosphatase. 
However, when Ca2+ uptake exceeds a threshold that is dependent on the presence of 
sensitizers like ROS, it triggers opening of the permeability transition pore (PTP), which 
often initiates execution of the cell. These broadly relevant effects of mitochondrial Ca2+ 
uptake indicate that it has to be carefully controlled. Control of mitochondrial Ca2+ 
uptake can occur through a change in its driving force or the permeability of MCU. The 
latter is regulated for example by the Ca2+ sensing MICU1 protein that supports closure 
of the MCU at low and cooperative activation of the MCU at high [Ca2+]c [53-55]. 
Another regulatory factor that was recognized at the same time as mitochondrial Ca2+ 
uptake was discovered, is the availability of Pi [56]. 
     
Substantial net Ca2+ uptake by mitochondria requires the presence of anions, like Pi, 
acetate, hydroxybutyrate, glutamate, and bicarbonate but not nitrate, that can provide 
a H+ source for the H+ pumps of the respiratory chain. In the absence of an adequate 
anion, the Ca2+ uptake is suppressed, m and O2 consumption are low and the matrix 
becomes highly alkalinic [57]. In addition, Pi uptake helps the formation of insoluble Pi 
salts, hydroxyapatite and whitlockite [56, 58] in the matrix and in turn, keeps the ionized 
[Ca2+]m at a relatively low level [59, 60] (Figure 1). This is important because the 
osmotically inactive precipitates help to control matrix expansion and because a 
progressive increase in the ionized [Ca2+]m would greatly stimulate mitochondrial Ca2+ 
efflux and in turn, would limit net mitochondrial Ca2+ uptake [61]. Thus, Pi can both 
stimulate the mtCU-mediated Ca2+ influx and suppress the exchanger-mediated Ca2+ 
efflux. None of the above listed anions can substitute for Pi in this regard.  
 
Pi uptake can also be mediated by the DIC and the ATP-Mg/Pi carriers [39, 62] (Figure 
1) but the primary pathway likely is provided by the PiC [40]; however, this evidence 
rests on potentially non-specific reagents such as NEM and mersalyl. Notably, PiC has 
also been proposed to undergo a Ca2+-induced cyclophilin D (CyPD)-mediated 
conformational change providing a mechanism central to the opening of the PTP [63]. 
However, a requirement for PiC in PTP opening remains debated [44, 64].   
 
In summary, Pi transport-mediated control of mitochondrial Ca2+ handling has been well 
established and circumstantial evidence supports a major role for PiC in this paradigm. 
The high turnover rate of the PiC is an advantage to enable Pi to effectively buffer Ca2+ 
that enters at a high rate through an ion channel. The next section describes genetic 
strategies that have been developed to address more directly the role of PiC in PTP 
opening and calcium handling in murine models [44, 45]. 
 
Slc25a3 mouse phenotypes  
Recently, the Baines and Molkentin groups have produced mice with both elevated and 
decreased cardiac expression of PiC. The two transgenic lines showed ~5 fold 
expression of PiC without a significant change in ANT and ATP synthase proteins, 
cardiac size and function [44]. Mitochondria isolated from the transgenic hearts showed 
unaltered respiration, ATP level, Ca2+ retention and activation of the PTP.  
 
In the first set of complementing studies, shRNA was used to attain ~60% reduction in 
cardiac PiC protein abundance without altering ANT and ATP synthase [44]. The heart 
showed hypertrophy and slightly decreased fractional shortening. Mitochondrial 
respiration and Ca2+ retention were unaltered but the steady-state ATP level was 
decreased. In parallel studies, inducible and cardiac-specific deletion of PiC was 
established [45]. In this model, drug-induction resulted in >90% decrease in PiC protein, 
whereas other respiratory chain proteins were unaltered. Similar to the shRNA-
mediated PiC silencing, cardiac hypertrophy was observed though cardiac shortening 
remained unaffected. Strikingly, time-dependent mitochondrial phosphate uptake was 
eliminated and the mitochondrial ATP level was decreased but Ca2+ retention was not 
impaired and was in fact increased.  
 
The lack of a phenotype for the PiC transgenic mouse likely indicates that the 
abundance of PiC does not limit the transport and potential other functions of PiC in 
mouse heart, which is in accordance with the exceptionally high turnover high turnover 
rate of the PiC. The cardiac hypertrophy and energy deficit observed upon PiC 
depletion is in line with the phenotype of the ANT knockout mouse, in which another 
component of the ATP synthasome is missing [65]. Thus, a major reason for the 
phenotype can be insufficient Pi transport and oxidative phosphorylation. Although PiC 
has been shown to interact with CyPD, a regulator of the PTP, the lack of a change in 
PTP activation in the PiC deficient mitochondria is not unexpected because CyPD as a 
chaperone also interacts with several proteins unrelated to the PTP. Perhaps the most 
surprising finding is that PiC-deficient mitochondria are competent to take up Ca2+ and 
Ca2+ uptake happens without greater expansion of the matrix. Although the DIC and the 
ATP-Mg/Pi carriers could provide surrogate phosphate uptake pathways, no time-
dependent mitochondrial Pi uptake was documented in this study [45]. Since Pi uptake 
was not measured during Ca2+ uptake, a possibility remains that Ca2+-stimulated Pi 
uptake also occurred in the mitochondria lacking PiC. 
 
Pathogenic mutations in the human PIC gene  
The first disease-associated PiC mutations were described in 2007. Two different 
mutations that affect only exon 3A and therefore the PiC-A isoform [42, 66, 67] were 
first observed in two different families of Turkish origin [42, 66]. More recently, one of 
these mutations (c.215G>A) was found in a third Turkish family (Mayr J.A. et al, 
unpublished). Remarkably the c.158-9A>G mutation, which results in a gain of a splice-
acceptor, was also reported in a family of Guatemalan origin [67], suggesting that at 
least this mutation has a widespread prevalence. Furthermore, mutations in regions 
outside of exon 3 have also been described, which affect both PiC-A and B isoforms 
[67]. Every patient presented mainly with cardiomyopathy regardless of the involvement 
of only the A or A and B isoforms. Elevated lactate and skeletal myopathy were also 
displayed by every patient of PiC-A specific mutation. The prevalence of pathogenic PiC 
mutations may be significantly underestimated because the cardiac impairments can be 
fatal early after birth, or can mimic other forms of hypertrophic cardiomyopathy. 
Furthermore, symptoms may not be distinct enough to suggest a PiC dysfunction. One 
remarkable feature common to patients with SLC25A3 mutations is the lack of 
neurocognitive involvement, when compared to other mitochondrial disorders causing 
cardiomyopathy [66, 67].  
 
The major difference in the symptoms associated with the PiC-A mutations compared to 
those associated with the mutations affecting both isoforms (see Table 1) might be 
explained by several factors, including tissue specific expression and distinct enzymatic 
activity of each isoform. The predominant involvement of cardiac and skeletal muscle in 
mitochondrial PiC deficiency can be explained by tissue specific isoforms of the 
enzyme, which are formed by tissue specific alternative splicing. It is also known that 
the transport affinity for Pi of PiC-A is 3-fold higher than that of PiC-B, whereas the 
maximal transport rate of PiC-B is 3-fold higher compared to PiC-A [24]. However, it is 
unknown how tissue function is affected by changes in the ratio of these two isoforms 
[67].  
 
Another intriguing aspect of the human PiC mutations is that they appear to be at least 
partially functionally compensated to allow survival despite a severe clinical situation 
during infancy. Similar compensation has also been documented in Barth syndrome [68] 
and in TMEM70 deficiency [69], which, like PiC deficiency, are primary mitochondrial 
diseases caused by mutations in nuclear-encoded genes. These diseases also manifest 
as life threatening diseases during early infancy but show a stabilization or even 
improvement of the cardiac impairment if patients survive the first years of life. Thus PiC 
deficiency is not the only primary mitochondrial disease with a severe clinical 
presentation during infancy but with some surviving adults. The compensatory 
mechanisms have not been identified for PiC or for these other deficiencies. In a 
skeletal muscle biopsy from one of the surviving individuals harboring a pathological 
PiC-A variant, there was evidence for elevated mitochondrial biogenesis [66]. However, 
this alone would be unlikely to compensate for PiC-A deficiency. In this same individual, 
there was essentially no PiC protein evident on a western blot, and there was only a 
very low signal on immunohistochemistry. Since the antibody that was used detects 
both isoforms, no or only a small compensatory increase in PiC-B protein occurred [66]. 
It is more likely that, in this individual, functional compensation has been achieved by 
the alteration of one or more metabolic pathways. An upregulation of glycolytic ATP 
production is one possibility. But there are, at least theoretically, other less obvious 
candidates, such as increased PiC transport through the DIC. This possibility has not 
been formally tested. Even the entry of modest amounts of Pi into mitochondria could 
be beneficial. For example, a decreased level of Pi could continue to support the 
phosphorylation of ADP. This could prevent a large depolarization with consequent 
mitochondrial ATP consumption [58]; such a mechanism would spare cytosolic ATP 
pools. Interestingly, in yeast, destabilization of the ATP synthase was compensated by 
ATP production via substrate level phosphorylation of ADP within mitochondria [70], 
demonstrating that this type of metabolic reconfiguration can arise in an intact organism. 
 
Future directions 
The basic biophysical and molecular characteristics of mitochondrial Pi transport and 
the PiC were established many years ago. Yet, the questions, and even surprises, that 
arise from the more recently discovered human PiC mutations and the PiC mouse 
models bring fresh relevance to the study of the PiC. The clinical picture of individuals 
with PiC mutations raises new and fundamental questions about the relationship 
between the A and B isoforms, the basis for the healthy survival of some of affected 
individuals, and the lack of neurological symptoms despite severe cardiomyopathy due 
to mutations affecting both isoforms. Indeed, while the mutations affecting both isoforms 
are predicted to be pathogenic, a more complete understanding of these mutations is 
needed. Regarding Ca2+, its effective mitochondrial uptake in the mouse model, with 
almost complete depletion of both isoforms, is surprising [45].  Therefore, the precise 
role of the PiC in mitochondrial Ca2+ uptake requires further investigation. Since Pi likely 
is a primary factor in mitochondrial matrix Ca2+ buffering that shows remarkable 
adaptive changes during both acute and prolonged increases in mitochondrial Ca2+ 
uptake [53, 59], the mechanisms of the coordination of the transports of Pi and Ca2+ is 
of great interest. Although mitochondrial ATP production is an obvious major target of 
PiC deficiency, downstream effects of a limitation in mitochondrial ATP production may 
have their own consequences. In this regard, OPA1-mediated IMM fusion is sensitive to 
the level of oxidative phosphorylation (Mishra et al. 2014), and mitochondrial fusion can 
function to acutely preserve ATP production in response to stress [71-73]. Thus the PiC 
should be crucial to the effectiveness of this stress response. For all of the above 
questions, the PiC mouse models, as well as the natural models presented by the 
human PiC mutations will be valuable as both tools and sources of information. Finally, 
ongoing improvements in gene sequencing technology, coupled with a greater 
awareness of PiC mutations, may significantly expand the population of identified 
individuals, making a further understanding of these mutations, and of the PiC more 
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Figure 1. Mitochondrial Pi transport and its coordination with ATP synthesis and Ca
2+ 
homeostasis  
H2PO4- (shown as Pi), H+, Ca2+, Mg2+, adenine nucleotides traverse the OMM via voltage-
dependent anion selective channels (VDAC). The PiC mediates electroneutral co-transport of Pi 
and H+ across the IMM. Pi is used for both phosphorylation of ADP (entering the matrix through 
ANT) by the ATP synthase, and chelation of Ca2+ in the matrix to form osmotically neutral 
hydroxyapatite and whitlockite. H+-s entering through the PiC support respiration and are 
pumped out by the respiratory complexes (RC). Alternative, probably lesser capacity, Pi uptake 
mechanisms are provided by the DIC and ATP-Mg/Pi carriers (SCaMC). The scheme also 
shows a major source of mitochondrial Ca2+ uptake, the local Ca2+ transfer from the ER 
(endoplasmic reticulum), mediated by the IP3 receptor Ca2+ release channels (IP3R) in the ER 
and the uniporter, which is formed by proteins including MCU oligomers, MICUs and EMRE in 
the IMM. Rapid and intense matrix Ca2+ loads provided by this pathway are compensated by 
fast Pi uptake mediated by the PiC, and possibly by the DIC under some conditions. Please 
note that the relative sizes and shape of intermembrane space and cristae are altered to 





Table 1. All reported cases of pathologic SLC25A3 variants. 
 Family 1   Family 2  Family 3 Family 4 
 Patient 1 - 1 Patient 1 - 2 Patient 1 - 3 Patient 2 - 1 Patient 2 - 2 Patient 3 - 1 Patient 4 - 1 
Reference Mayr et al. 2011 Mayr et al. 2011 Mayr et al. 2011 Mayr et al. 2007 Mayr et al. 2007 Bhoj et al. 2014 Bhoj et al. 2014 
Ethnicity Turkish Turkish Turkish Turkish Turkish Guatemalan Haitian/Dominican 
Gender Female Male Male Female Female Male Male 
Current 
age 
Died at 6 
months 
9 years, stable 17 years, stable Died at 4 
months 
Died at 9 
months 


















































at term.  
 
Birth weight: 
3000 g,  
 
Apgar score of 3 
at 1 minute and 
9 at 5 minutes.  
 









2600 g (10%),  
 
Apgar score of 9 
at 1 minute and 
10 at 5 minutes.  
 





at term.  
 
Birth weight: 
2870 g (10%),  
 
Apgar score of 8 
at 1 minute and 
10 at 5 minutes, 
 









3990 g (75%),  
 
Apgar score of 7 
at 1 minute and 8 
at 5 minutes.  
 









Gestation: born at 
term.  
 
Birth weight: 2849 g 
(50%), 
 
Apgar score of 8 at 1 
minute and 9 at 5 
minutes.  
 
At 4 wks: worsening 
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Figure 1. Mitochondrial Pi transport and its coordination with ATP synthesis and Ca2+ homeostasis 
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